Developer docs
API playgroundTry for free, no card

Search company profiles

Ally Bridge Group

Full company profile

uuid00006eo

Namestring
Ally Bridge Group
Legal namestring
Ally Bridge Group (NY) LLC / Ally Bridge Group (HK) Limited
Websiteurl
ally-bridge.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu and operating from offices in New York (430 Park Avenue) and Hong Kong (Cheung Kong Center II) through Ally Bridge Group (NY) LLC and Ally Bridge Group (HK) Limited. The firm manages capital across two complementary strategies: a Private Equity platform established in 2013 and a long-biased Public Equity strategy launched in 2018, with stated cumulative led or co-led transaction volume of over $6-7 billion across healthcare subsectors spanning medical technology, biotechnology, single-cell tools and diagnostics, digital health, healthcare services, focused ultrasound, surgical robotics, and antibody-drug conjugates.

The firm's underlying investment platform is its core offering rather than a software product: it combines a scientific and clinical research bench (team includes PharmDs, PhDs, and MDs) with M&A and capital markets expertise to source, underwrite, and lead healthcare financings across the capital structure, from late-stage private rounds (typically targeting companies with $30-50M+ revenue and 50%+ gross margins) through PIPEs and post-IPO positions. Ally Bridge typically invests as a lead or co-lead alongside healthcare-dedicated and generalist sponsors including Longitude Capital, Andera Partners, SoftBank Vision Fund 2, OrbiMed, Bain Capital, Janus Henderson, and Catalio, and holds board seats at multiple portfolio companies (Imperative Care, ProfoundBio, Kestra, Biobeat, Cardiac Dimensions, Epicrispr, VitalConnect, SetPoint, ProMIS).

The revenue model is standard alternative asset management economics: recurring management fees on assets under management across the private and public equity strategies, supplemented by carried interest on private equity funds and performance fees on the public equity strategy. Capital is raised bilaterally from institutional LPs (endowments, family offices, pension funds, sovereign wealth funds) by a dedicated investor relations team led by Managing Director Zain Shekhani for private equity, with portfolio companies serving as investees rather than fee-paying customers. Notable transactions include the WuXi PharmaTech $3.3 billion take-private (2015) and subsequent Hong Kong IPOs of WuXi Biologics (2017) and WuXi AppTec (2018), the CMR Surgical $600 million Series D (2021, co-led with SoftBank Vision Fund 2), Kestra Medical Technologies $196 million (2024), Insightec $150 million (2024), ProMIS Neurosciences up to $175 million PIPE (2026), and ProfoundBio (acquired by Genmab for $1.8 billion in May 2024).

Short descriptiontext

Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu, operating dual private equity and long-biased public equity strategies from New York and Hong Kong to deploy over $6 billion in led and co-led healthcare transactions across medtech, biotech, tools/diagnostics, and digital health for institutional limited partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare investment management, life sciences private equity, healthcare venture capital, public equity strategy, cross-border healthcare investing
Industry4 codes
PRIMARYFSAEAGAH
Cross-Border M&A Advisory
SECONDARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
SECONDARYBPAHADAO
Infrastructure & Project Finance Advisory
NAICS code3 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Other Financial Vehicles52599
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Investment Management
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Investment management fees
TypeManaged Services
Description

Recurring management fees on assets under management across private equity and public equity fund strategies. Private equity platform established in 2013; public equity long-biased strategy launched in 2018. Standard industry model for alternative asset managers.

ally-bridge.com
2Carried interest / performance fees
TypeProfessional Services
Description

Performance-based economics (carried interest on private equity funds and performance fees on public equity strategy) tied to investment outcomes for investors.

ally-bridge.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ally Bridge Group manages two complementary healthcare-focused investment strategies from offices in New York and Hong Kong: a Private Equity Platform (established 2013) that leads or co-leads growth and late-stage financings across medtech, biotech, tools/diagnostics, and digital health, and a long-biased Public Equity Strategy (launched 2018) that invests across the global healthcare industry. The firm has led or co-led over $6 billion of healthcare transactions and selectively underwrites companies addressing unmet medical needs, blending deep scientific and clinical research with M&A and capital markets expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over $7 billion of healthcare transactions led or co-led since 2013
+3 more records
Product overview1 text field

Ally Bridge Group is a global healthcare investment management firm, not a software/product company. Its offering is a two-strategy investment platform composed of the Private Equity Platform (the firm's initial platform, established in 2013) and the Public Equity Strategy (a long-biased strategy launched in 2018). Together, these two complementary strategies allow Ally Bridge Group to invest across the capital structure in private and public healthcare/life science opportunities globally, with assets managed from offices in New York and Hong Kong. The firm seeks to deliver superior risk-adjusted returns by blending deep scientific and clinical research with M&A and capital markets expertise.

Product and service2 records
1Private Equity Platform
CategoryPrivate Equity Fund
Description

Ally Bridge Group's original investment platform, established in 2013, that executes lead or co-lead private investments in healthcare and life science companies across medtech, biotech, tools/diagnostics, digital health, and healthcare services. The firm has led or co-led over $6 billion of healthcare transactions through this platform and selectively underwrites later-stage companies with $30M-$50M+ revenue and 50%+ gross margins addressing unmet medical needs. Targeted at institutional limited partners (LPs) and targeted portfolio companies.

2Public Equity Strategy
CategoryPublic Equity Fund / Long-Biased Hedge Fund
Description

A long-biased public equity investment strategy launched in 2018, complementing the Private Equity platform. It enables the firm to invest across the global healthcare industry across the capital structure, with public equity leadership based in New York. The strategy invests in publicly traded healthcare companies globally and is overseen by a dedicated CIO (Slanix Paul Alex) and operations/finance team. Targeted at institutional limited partners and the firm's public equity LPs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Ally Bridge Group entered into a strategic partnership with LifeTech Scientific Corporation (SEHK) in January 2018 for China-global medtech investment and operating collaboration. The partnership was extended in April 2019 with a three-way China joint venture between Ally Bridge Group, LifeTech Scientific, and Quantum Surgical to develop an innovative surgical robot for liver cancer treatment in China.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Boston-based healthcare-focused crossover fund that invests across public and private markets and frequently co-invests with Ally Bridge in late-stage biotech and medtech rounds. Most directly comparable in dual public/private healthcare strategy and late-stage investment focus.

TypeBroad incumbent
Description

Large global healthcare-dedicated investment firm with private equity, public equity, royalties and credit strategies. Directly comparable in healthcare specialization and recurring co-investor alongside Ally Bridge (e.g., Biobeat, Aerin Medical, ProfoundBio, Endeavor BioMedicines).

TypeDirect peer
Description

Healthcare-focused growth equity firm investing in late-stage biotech, medtech and digital health. Frequently co-leads rounds with Ally Bridge (e.g., Kestra Medical, Imperative Care) and matches the late-stage, science-driven investment profile.

TypeBroad incumbent
Description

Healthcare-focused arm of Bain Capital investing across the life sciences capital structure. Regular co-investor with Ally Bridge (Imperative Care, Kestra Medical) with significantly larger AUM but the same late-stage healthcare thesis.

TypeBroad incumbent
Description

Healthcare-focused investment manager with life sciences and private credit strategies, frequently co-investing in PIPE and growth rounds with Ally Bridge (ProMIS Neurosciences, Imperative Care convertible, Insightec). Closely comparable as a healthcare-only investor.

TypeDirect peer
Description

European healthcare-focused growth equity firm (formerly Edmond de Rothschild). Repeated co-lead partner with Ally Bridge on Kestra Medical and other medtech rounds, sharing the late-stage healthcare specialty.

TypeDirect peer
Description

Healthcare-dedicated crossover fund investing in biotech and medtech across private and public markets. Co-led Kestra Medical with Ally Bridge and shares the dual-strategy late-stage healthcare thesis.

TypeDirect peer
Description

Global healthcare-specialist manager with a long history of biopharma and medtech investment; recently featured alongside Ally Bridge as a 2026 biotech rebound investor. Highly comparable in healthcare-only mandate and public/private crossover activity.

TypeBroad incumbent
Description

Large, multi-stage venture firm with deep healthcare practice across biotech, medtech and digital health. Co-invested with Ally Bridge in TESARO PIPE (2016) and SetPoint Medical, sharing late-stage healthcare exposure at much greater AUM scale.

TypeBroad incumbent
Description

Healthcare-focused crossover funds that invest across private and public healthcare and frequently co-invest with Ally Bridge (Insightec, Endeavor, ProfoundBio, Kestra Medical). Comparable in crossover mandate and healthcare-only focus at larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles26 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment132 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ally Bridge Group

Healthcare Investment Managementally-bridge.com

Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu, operating dual private equity and long-biased public equity strategies from New York and Hong Kong to deploy over $6 billion in led and co-led healthcare transactions across medtech, biotech, tools/diagnostics, and digital health for institutional limited partners.

What Ally Bridge Group does

Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu and operating from offices in New York (430 Park Avenue) and Hong Kong (Cheung Kong Center II) through Ally Bridge Group (NY) LLC and Ally Bridge Group (HK) Limited. The firm manages capital across two complementary strategies: a Private Equity platform established in 2013 and a long-biased Public Equity strategy launched in 2018, with stated cumulative led or co-led transaction volume of over $6-7 billion across healthcare subsectors spanning medical technology, biotechnology, single-cell tools and diagnostics, digital health, healthcare services, focused ultrasound, surgical robotics, and antibody-drug conjugates.

The firm's underlying investment platform is its core offering rather than a software product: it combines a scientific and clinical research bench (team includes PharmDs, PhDs, and MDs) with M&A and capital markets expertise to source, underwrite, and lead healthcare financings across the capital structure, from late-stage private rounds (typically targeting companies with $30-50M+ revenue and 50%+ gross margins) through PIPEs and post-IPO positions. Ally Bridge typically invests as a lead or co-lead alongside healthcare-dedicated and generalist sponsors including Longitude Capital, Andera Partners, SoftBank Vision Fund 2, OrbiMed, Bain Capital, Janus Henderson, and Catalio, and holds board seats at multiple portfolio companies (Imperative Care, ProfoundBio, Kestra, Biobeat, Cardiac Dimensions, Epicrispr, VitalConnect, SetPoint, ProMIS).

The revenue model is standard alternative asset management economics: recurring management fees on assets under management across the private and public equity strategies, supplemented by carried interest on private equity funds and performance fees on the public equity strategy. Capital is raised bilaterally from institutional LPs (endowments, family offices, pension funds, sovereign wealth funds) by a dedicated investor relations team led by Managing Director Zain Shekhani for private equity, with portfolio companies serving as investees rather than fee-paying customers. Notable transactions include the WuXi PharmaTech $3.3 billion take-private (2015) and subsequent Hong Kong IPOs of WuXi Biologics (2017) and WuXi AppTec (2018), the CMR Surgical $600 million Series D (2021, co-led with SoftBank Vision Fund 2), Kestra Medical Technologies $196 million (2024), Insightec $150 million (2024), ProMIS Neurosciences up to $175 million PIPE (2026), and ProfoundBio (acquired by Genmab for $1.8 billion in May 2024).

Ally Bridge Group firmographics

Firmographics
Name
Ally Bridge Group
Legal name
Ally Bridge Group (NY) LLC / Ally Bridge Group (HK) Limited
Website
https://ally-bridge.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu, operating dual private equity and long-biased public equity strategies from New York and Hong Kong to deploy over $6 billion in led and co-led healthcare transactions across medtech, biotech, tools/diagnostics, and digital health for institutional limited partners.
Ownership category
akta.pro rank

Ally Bridge Group industry classification

Industry
Product category
Healthcare Investment Management
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSAEAGAH
Cross-Border M&A Advisory
SECONDARYBPADACAJ
Private Sector & Blended Finance Arms (IFC-type)
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
SECONDARYBPAHADAO
Infrastructure & Project Finance Advisory

Keywords

  • Healthcare investment management
  • Life sciences private equity
  • Healthcare venture capital
  • Public equity strategy
  • Cross-border healthcare investing

Where Ally Bridge Group is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ally Bridge Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Investment management fees: Recurring management fees on assets under management across private equity and public equity fund strategies. Private equity platform established in 2013; public equity long-biased strategy launched in 2018. Standard industry model for alternative asset managers.
  2. Carried interest / performance fees: Performance-based economics (carried interest on private equity funds and performance fees on public equity strategy) tied to investment outcomes for investors.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Ally Bridge Group product offering

Product offering

Core offering

Ally Bridge Group manages two complementary healthcare-focused investment strategies from offices in New York and Hong Kong: a Private Equity Platform (established 2013) that leads or co-leads growth and late-stage financings across medtech, biotech, tools/diagnostics, and digital health, and a long-biased Public Equity Strategy (launched 2018) that invests across the global healthcare industry. The firm has led or co-led over $6 billion of healthcare transactions and selectively underwrites companies addressing unmet medical needs, blending deep scientific and clinical research with M&A and capital markets expertise.

Product overview

Ally Bridge Group is a global healthcare investment management firm, not a software/product company. Its offering is a two-strategy investment platform composed of the Private Equity Platform (the firm's initial platform, established in 2013) and the Public Equity Strategy (a long-biased strategy launched in 2018). Together, these two complementary strategies allow Ally Bridge Group to invest across the capital structure in private and public healthcare/life science opportunities globally, with assets managed from offices in New York and Hong Kong. The firm seeks to deliver superior risk-adjusted returns by blending deep scientific and clinical research with M&A and capital markets expertise.

Differentiator

Problem solved

Functional benefit

Products and services

  • Private Equity Platform Ally Bridge Group's original investment platform, established in 2013, that executes lead or co-lead private investments in healthcare and life science companies across medtech, biotech, tools/diagnostics, digital health, and healthcare services. The firm has led or co-led over $6 billion of healthcare transactions through this platform and selectively underwrites later-stage companies with $30M-$50M+ revenue and 50%+ gross margins addressing unmet medical needs. Targeted at institutional limited partners (LPs) and targeted portfolio companies.
  • Public Equity Strategy A long-biased public equity investment strategy launched in 2018, complementing the Private Equity platform. It enables the firm to invest across the global healthcare industry across the capital structure, with public equity leadership based in New York. The strategy invests in publicly traded healthcare companies globally and is overseen by a dedicated CIO (Slanix Paul Alex) and operations/finance team. Targeted at institutional limited partners and the firm's public equity LPs.

Quantifiable outcome

  • Over $7 billion of healthcare transactions led or co-led since 2013
  • +3 more outcomes

Companies that use Ally Bridge Group

Customer profile

Segments3 records

Ideal customer profiles2 records

Ally Bridge Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ally Bridge Group partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LifeTech Scientific CorporationflagshipStrategic or Co-development Partner · 1 January 2018Ally Bridge Group entered into a strategic partnership with LifeTech Scientific Corporation (SEHK) in January 2018 for China-global medtech investment and operating collaboration. The partnership was extended in April 2019 with a three-way China joint venture between Ally Bridge Group, LifeTech Scientific, and Quantum Surgical to develop an innovative surgical robot for liver cancer treatment in China.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Ally Bridge Group competitors and assessment

Company assessment

Broad incumbents

  • RA Capital Management: Boston-based healthcare-focused crossover fund that invests across public and private markets and frequently co-invests with Ally Bridge in late-stage biotech and medtech rounds. Most directly comparable in dual public/private healthcare strategy and late-stage investment focus.
  • OrbiMed Advisors: Large global healthcare-dedicated investment firm with private equity, public equity, royalties and credit strategies. Directly comparable in healthcare specialization and recurring co-investor alongside Ally Bridge (e.g., Biobeat, Aerin Medical, ProfoundBio, Endeavor BioMedicines).
  • Bain Capital Life Sciences: Healthcare-focused arm of Bain Capital investing across the life sciences capital structure. Regular co-investor with Ally Bridge (Imperative Care, Kestra Medical) with significantly larger AUM but the same late-stage healthcare thesis.
  • Perceptive Advisors: Healthcare-focused investment manager with life sciences and private credit strategies, frequently co-investing in PIPE and growth rounds with Ally Bridge (ProMIS Neurosciences, Imperative Care convertible, Insightec). Closely comparable as a healthcare-only investor.
  • New Enterprise Associates (NEA): Large, multi-stage venture firm with deep healthcare practice across biotech, medtech and digital health. Co-invested with Ally Bridge in TESARO PIPE (2016) and SetPoint Medical, sharing late-stage healthcare exposure at much greater AUM scale.
  • TCG Crossover (formerly The Column Group-adjacent) / T. Rowe Price Health Sciences: Healthcare-focused crossover funds that invest across private and public healthcare and frequently co-invest with Ally Bridge (Insightec, Endeavor, ProfoundBio, Kestra Medical). Comparable in crossover mandate and healthcare-only focus at larger scale.

Direct peers

  • Longitude Capital: Healthcare-focused growth equity firm investing in late-stage biotech, medtech and digital health. Frequently co-leads rounds with Ally Bridge (e.g., Kestra Medical, Imperative Care) and matches the late-stage, science-driven investment profile.
  • Andera Partners: European healthcare-focused growth equity firm (formerly Edmond de Rothschild). Repeated co-lead partner with Ally Bridge on Kestra Medical and other medtech rounds, sharing the late-stage healthcare specialty.
  • Omega Funds: Healthcare-dedicated crossover fund investing in biotech and medtech across private and public markets. Co-led Kestra Medical with Ally Bridge and shares the dual-strategy late-stage healthcare thesis.
  • Sofinnova Investments: Global healthcare-specialist manager with a long history of biopharma and medtech investment; recently featured alongside Ally Bridge as a 2026 biotech rebound investor. Highly comparable in healthcare-only mandate and public/private crossover activity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ally Bridge Group social profiles

Digital presence

Ally Bridge Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ally Bridge Group leadership team

Management profile

Number of profiles

Profiles26 records

Ally Bridge Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ally Bridge Group M&A and investment

M&A and investment

M&A

Investments132 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ally Bridge Group

What does Ally Bridge Group do?

Ally Bridge Group manages two complementary healthcare-focused investment strategies from offices in New York and Hong Kong: a Private Equity Platform (established 2013) that leads or co-leads growth and late-stage financings across medtech, biotech, tools/diagnostics, and digital health, and a long-biased Public Equity Strategy (launched 2018) that invests across the global healthcare industry. The firm has led or co-led over $6 billion of healthcare transactions and selectively underwrites companies addressing unmet medical needs, blending deep scientific and clinical research with M&A and capital markets expertise.

Is Ally Bridge Group a public or private company?

Ally Bridge Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ally Bridge Group founded?

Ally Bridge Group was founded in 2013. It employs 11 to 50 people.

Where is Ally Bridge Group based?

Ally Bridge Group is headquartered in New York, United States, in the North America region.

How does Ally Bridge Group make money?

Two revenue lines are on record. Investment management fees are the primary driver. The others are carried interest / performance fees.

Who are Ally Bridge Group's main competitors?

Broad incumbents on record are RA Capital Management, OrbiMed Advisors, Bain Capital Life Sciences, Perceptive Advisors, New Enterprise Associates (NEA) and TCG Crossover (formerly The Column Group-adjacent) / T. Rowe Price Health Sciences. Direct peers are Longitude Capital, Andera Partners, Omega Funds and Sofinnova Investments.

Does Ally Bridge Group have an API?

No public API is recorded for Ally Bridge Group.

What industry is Ally Bridge Group in?

Ally Bridge Group's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSAEAGAH, Cross-Border M&A Advisory, with a secondary code of BPADACAJ, Private Sector & Blended Finance Arms (IFC-type). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioXconomyThe IPO imperative: Why your biotech needs a seasoned CFOExperts at the BIO conference in San Diego emphasized that biotech companies seeking an IPO must hire a seasoned, full-time CFO with public market experience well before the crossover round to ensure success. Panelists from Sofinnova, Ally Bridge Group, Morgan Stanley, and Nasdaq warned that a limited supply of qualified candidates creates a competitive talent market where waiting too late could leave companies unable to secure necessary leadership.Defense WorldAlly Bridge Group NY LLC Takes $3.46 Million Position in Capricor Therapeutics, Inc. $CAPRAlly Bridge Group NY LLC purchased a new position of 113,899 shares in Capricor Therapeutics, Inc. during Q1, valued at approximately $3.46 million, representing 2.8% of the fund's portfolio. The investment comes amid significant regulatory headwinds for Capricor, including FDA briefing documents challenging the efficacy of its lead candidate deramiocel and an upcoming July 29 FDA advisory committee meeting to review the therapy. Additional pressures include law firm investigations into potential securities violations, analyst downgrades from Roth Capital and Alliance Global Partners, and notable insider selling by CFO Anthony Bergmann totaling 50,000 shares worth $1.55 million in the past 90 days.American Banking and Market NewsAlly Bridge Group NY LLC Buys New Holdings in Capricor Therapeutics, Inc. $CAPRAlly Bridge Group NY LLC acquired a new position in Capricor Therapeutics during the first quarter, purchasing 113,899 shares valued at approximately $3.46 million, joining several other institutional investors who also increased or initiated stakes in the biotechnology company. The article reports multiple headwinds for Capricor, including FDA briefing documents challenging the efficacy of its deramiocel therapy ahead of a July 29 advisory committee meeting, law firm investigations into potential securities law violations, analyst downgrades, and a 6% stock decline. Capricor Therapeutics, headquartered in Beverly Hills, California, is developing cell-based therapeutics for cardiovascular and rare diseases including Duchenne muscular dystrophy.Defense WorldAlly Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATXAlly Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. during Q1, purchasing 926,557 shares valued at approximately $3.86 million, making it the stock's 14th largest holding at 3.1% of its portfolio. Several other institutional investors, including Commodore Capital LP, Affinity Asset Advisors LLC, Spruce Street Capital LP, and Opaleye Management Inc., also purchased or increased their positions in the company during the same period. Analysts maintain a consensus "Buy" rating on the stock with an average price target of $12.62.MarketBeatAlly Bridge Group NY LLC Acquires 12,928 Shares of Praxis Precision Medicines, Inc. $PRAXAlly Bridge Group NY LLC increased its stake in Praxis Precision Medicines by 65.0% during the first quarter, acquiring an additional 12,928 shares to hold a total of 32,810 shares. Several other institutional investors, including Parallel Advisors LLC and Danske Bank A S, also adjusted their holdings in the clinical-stage biopharmaceutical company during the recent quarters.BioSpaceAdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing InfrastructureAdvanCell closed a $315 million Series D financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from new investors including Bain Capital Life Sciences and Fidelity. Proceeds will advance ADVC001, a Lead-212 PSMA-targeted therapy for metastatic prostate cancer, toward Phase 3 development and expand its vertically integrated manufacturing infrastructure.Pulse 2.0AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha TherapiesAdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of a $315 million Series D financing round led by Ally Bridge Group and co-led by Alpha Wave, with participation from multiple institutional investors including Bain Capital Life Sciences, Fidelity, T. Rowe Price, and others. The financing will advance ADVC001, AdvanCell's Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer, toward Phase 3 clinical development while expanding U.S. manufacturing infrastructure and isotope supply. Andrew Lam of Ally Bridge Group and Nik Economopoulos of Alpha Wave will join AdvanCell's Board of Directors concurrent with the round.citybizAdvanCell, T. Rowe Price Associates Back $315M Financing to Expand Targeted Alpha Therapy PlatformAdvanCell has closed a US$315 million Series D financing round, led by Ally Bridge Group and co-led by Alpha Wave, with participation from multiple investors including Bain Capital Life Sciences, Fidelity, T. Rowe Price Associates, and Eli Lilly and Company. The funding will advance ADVC001, the company's Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer, into Phase 3 clinical development while expanding U.S. manufacturing infrastructure and isotope supply capabilities. The clinical-stage radiopharmaceutical company operates across North America and Australia and is building a vertically integrated platform spanning isotope supply, manufacturing, and clinical development.FierceBiotechBig Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metalAdvanCell, a radiotherapy company, has closed a $315 million Series D funding round led by Ally Bridge Group and Alpha Wave, with participation from Sanofi Ventures, Eli Lilly and Bain Capital Life Sciences, to advance its lead prostate cancer candidate ADVC001 into Phase 3 development. The biotech's lead asset uses lead-212, an alpha emitter that causes double-strand DNA breaks, which the company argues is more effective than Novartis' Pluvicto, the current standard-of-care beta emitter. AdvanCell has established its U.S. headquarters in Boston while maintaining operations in Australia, with plans to scale up manufacturing in the U.S. ahead of the Phase 3 trial.The Pharma LetterAdvanCell raises $315 million to accelerate lead-212 radiopharma pipelineAdvanCell closed an oversubscribed $315 million Series D financing to advance its lead-212 radiopharma pipeline and expand manufacturing. The round was led by Ally Bridge Group and co-led by Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity, T Rowe Price, and others.